The EC has granted orphan drug designation to CPV-104 for treating C3 Glomerulopathy (C3G). The company will initiate patient dosing in its first clinical trial during H1’25
The ODD, based on COMP’s positive opinion, will grant Eleva 10yrs. of market exclusivity along with incentives such as eligibility for protocol assistance and possible exemptions or reductions in certain regulatory fees
The preclinical study of CPV-104 (recombinant human complement Factor H) showed its ability to act as an analogue of human Factor H, normalizing serum C3 levels & degrading C3 deposits in the kidney
Ref: Eleva | Image: Eleva
Related News:- Novartis Reports Positive Results of Iptacopan in P-III (APPEAR-C3G) for the Treatment of C3 glomerulopathy (C3G)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
